Immutep Announces First-in-Human Phase I Study Of IMP761 Has Been Fully Recruited And Drug Has Been Administered With No Safety Issues
Portfolio Pulse from Benzinga Newsdesk
Immutep has announced that its first-in-human Phase I study of IMP761 has been fully recruited and the drug has been administered without any safety issues.
October 17, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's successful recruitment and administration of IMP761 in its Phase I study without safety issues is a positive development, potentially boosting investor confidence.
The completion of recruitment and administration of IMP761 without safety issues is a significant milestone for Immutep, indicating progress in their clinical trials. This can lead to increased investor confidence and potentially a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100